PCT offers guidance for every stage of your process, from understanding and defining your product’s attributes all the way through commercial-stage manufacturing. We can build a roadmap for your therapy that will help you avoid obstacles and accelerate progress towards successful commercialization. By offering our clients consultative services that are founded upon a Development by Design approach, we can be your go-to partner for the entire journey of your cell therapy.
PCT offers several consulting services to help build and establish a long-term vision with commercialization in mind.
A Quality Risk Assessment (QRA) from PCT helps you identify potential risks in a product’s assay profile, including safety, identity,
At its core, the Strategic Manufacturing Assessment (SMA) is an independent, disciplined, and diagnostic evaluation of a cell therapy process that can be completed in six to eight weeks.
The Strategic Commercial Manufacturing Plan (SCMP) is a robust plan that includes and exceeds the content of the Strategic Manufacturing Assessment and Quality Risk Analysis.
In addition to these three offerings, PCT can customize consultative services and personalized guidance for process optimization based on the size, scope, and clinical stage of any client’s cell therapy product. Some areas in which we can work with clients include: